Fangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership
Reuters
Oct 29
Fangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership
Fangzhou Inc., a leader in AI-driven Internet healthcare solutions, has entered into a strategic collaboration with Shanghai Fosun Pharmaceutical (Fosun Pharma) to advance AI-powered psoriasis management. The partnership will leverage Fangzhou's proprietary AI technologies, including its "XingShi" Large Language Model and AI Health Manager, alongside Fosun Pharma's expertise and products such as Otezla® for psoriasis treatment. Together, the companies aim to develop a comprehensive digital health platform that offers personalized care, medication guidance, and ongoing support for patients with psoriasis and other autoimmune conditions. The initiative is designed to improve long-term disease management and support the goals of the Healthy China 2030 initiative.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fangzhou Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564300-en) on October 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.